focus -WSS

focus

author：explore 2025-09-28 01:36:27 - browse：7566

Micrograph of ulcerative colitis -- biotech coverage from STAT — Micrograph of chronic active ulcerative colitis in a biopsy specimen. Wikimedia Commons

Checkpoint inhibitors, drugs that unleash the immune system, have turned into blockbuster therapies that have transformed outcomes for some patients with deadly cancers. AltruBio, a Bay Area biotech, is betting it can help patients suffering from autoimmune and inflammatory diseases by taking the opposite tack: pumping the brakes on runaway immune responses.

The company on Tuesday announced that it has raised $225 million in a Series B venture round led by BVP Partners, with the biotech’s backers also including RA Capital Management, Cormorant Asset Management, and Soleus Capital. AltruBio plans to put that money toward advancing a drug that is already being tested in a mid-stage trial for ulcerative colitis, an increasingly competitive market in which a number of pharma companies have launched drugs.

It’s the latest example of intense investor interest in immunology-focused companies. Firms such as Paragon Therapeutics and Prometheus Laboratories have recently been at the center of financing mega-rounds, and Blackstone Life Sciences recently committed up to $300 million to launch Uniquity Bio, a company developing treatments for asthma and chronic obstructive pulmonary disease.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： A rare thyroid diagnosis led to unexpected, all

hotspot

WSS

FDA panel to weigh safety of artificial wombs for preterm births

NIH nominee Bertagnolli will get October confirmation hearing

The 10 drugs up first for Medicare price negotiation

Trump surgeon general acknowledges mistakes during Covid

Neurocrine congenital adrenal hyperplasia trial succeeds

Covid hospitalizations on the rise, Humana says

leisure time

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Continuity nursing helped my family in our darkest PICU moments

Why Novartis is changing the name of its research labs

Novavax promises a turnaround & Lilly roils the obesity market

Snackable artificial intelligence, expert AI, and the pharma industry

Walensky prepares to leave CDC — and Congress — behind

A new House health package & hospitals’ new site

ChatGPT in medicine: STAT answers readers' burning questions

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

State Dept. review finds Biden bears some blame for Afghanistan failures

Medicare to pay more for cardiac rehab in hospital outpatient clinics

hotspot

Why Novartis is changing the name of its research labs

How to protect patients from sexual assault

Chamber of Commerce, DOJ clash in court over drug prices

PBMs drew scrutiny in House hearing — and so did pharma

Illumina names Agilent executive as new CEO

FDA panel to weigh safety of artificial wombs for preterm births

explore

Wikipedia

hotspot

entertainment